Primary endpoint achieved: PVX108 therapy increased the maximum tolerated dose of peanut compared to placebo following a convenient, once- monthly treatment course over 12 months, while demonstrating a highly favourable safety and tolerability profile Multiple secondary and exploratory objectives were also met, including a significant reduction in emotional impact of allergy reported by children following […]